 Fulcrum Therapeutics Inc NASDAQ: FULC has announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 trial of FTX-6058 for sickle cell disease and other hemoglobinopathies, such as beta-thalassemia. The Company also shared new preclinical mechanism data showing that FTX-6058 downregulated known repressors of fetal hemoglobin HbF. 